Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers
Annemiek Vermeeren, Stefan Jongen, Patricia Murphy, et al.
SLEEP (2018) Vol. 42, Iss. 4
Open Access | Times Cited: 215

Showing 1-25 of 215 citing articles:

Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2
Mikko Kärppä, Jane Yardley, Kate Pinner, et al.
SLEEP (2020) Vol. 43, Iss. 9
Open Access | Times Cited: 127
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 11, pp. 1063-1078
Closed Access | Times Cited: 70
The orexin story and orexin receptor antagonists for the treatment of insomnia
Clemens Muehlan, Catherine Roch, Cédric Vaillant, et al.
Journal of Sleep Research (2023) Vol. 32, Iss. 6
Open Access | Times Cited: 39
Lemborexant: First Approval
Lesley J. Scott
Drugs (2020) Vol. 80, Iss. 4, pp. 425-432
Closed Access | Times Cited: 62
Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies
Russell Rosenberg, Leslie Citrome, Christopher L. Drake
Neuropsychiatric Disease and Treatment (2021) Vol. Volume 17, pp. 2549-2566
Open Access | Times Cited: 47
Efficacy of Lemborexant in Adults ≥ 65 Years of Age with Insomnia Disorder
Valerie Arnold, Sonia Ancoli‐Israel, Thien Thanh Dang‐Vu, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 4, pp. 1081-1098
Open Access | Times Cited: 6
New drug approvals for 2019: Synthesis and clinical applications
Shuo Yuan, Bin Yu, Hong‐Min Liu
European Journal of Medicinal Chemistry (2020) Vol. 205, pp. 112667-112667
Closed Access | Times Cited: 49
Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy Adults
Ishani Landry, Kenya Nakai, Jim Ferry, et al.
Clinical Pharmacology in Drug Development (2020) Vol. 10, Iss. 2, pp. 153-165
Open Access | Times Cited: 48
Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease
J Kron, Ryan J. Keenan, Daniël Hoyer, et al.
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 359-386
Open Access | Times Cited: 15
Psychotropic Drugs in Special Conditions

(2025), pp. 913-926
Closed Access
Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials
Margaret Moline, Gary Zammit, Jane Yardley, et al.
Postgraduate Medicine (2020) Vol. 133, Iss. 1, pp. 71-81
Open Access | Times Cited: 36
Prescriber's Guide
Stephen M. Stahl
(2020)
Closed Access | Times Cited: 33
Driving Performance after Bedtime Administration of Daridorexant, Assessed in a Sensitive Simulator
Clemens Muehlan, Sander Brooks, Cédric Vaillant, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 111, Iss. 6, pp. 1334-1342
Open Access | Times Cited: 20
Orexin dual receptor antagonists, zolpidem, zopiclone, eszopiclone, and cognitive research: A comprehensive dose-response meta-analysis
Mengzhen Zhou, Jiyou Tang, Shasha Li, et al.
Frontiers in Human Neuroscience (2023) Vol. 16
Open Access | Times Cited: 11
The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act
Margaret Moline, Shoji Asakura, Carsten Beuckman, et al.
Psychopharmacology (2023) Vol. 240, Iss. 4, pp. 699-711
Open Access | Times Cited: 11
Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice
Carrie E. Mahoney, Takatoshi Mochizuki, Thomas E. Scammell
SLEEP (2019) Vol. 43, Iss. 6
Open Access | Times Cited: 30
A Comprehensive Review of Lemborexant to Treat Insomnia.
Mitchell C. Fuller, Samuel F. Carlson, Chris M. Grant, et al.
PubMed (2024) Vol. 54, Iss. 1, pp. 43-64
Closed Access | Times Cited: 3
Efficacy and safety of insomnia treatment with lemborexant in older adults: analyses from three clinical trials
Mark H. Gotfried, Sanford Auerbach, Thien Thanh Dang‐Vu, et al.
Drugs & Aging (2024) Vol. 41, Iss. 9, pp. 741-752
Open Access | Times Cited: 3
Residual effects of medications for sleep disorders on driving performance: A systematic review and network meta-analysis of randomized controlled trials
Michele Fornaro, Claudio Caiazza, Flavia Rossano, et al.
European Neuropsychopharmacology (2024) Vol. 81, pp. 53-63
Closed Access | Times Cited: 2
Guideline for evaluating the effects of psychotropic drugs on motor vehicle driving performance in Japan: A tiered approach for the assessment of clinically meaningful driving impairment
Tetsuo Nakabayashi, Kunihiro Iwamoto, Akiko Yamaguchi, et al.
Neuropsychopharmacology Reports (2024) Vol. 44, Iss. 2, pp. 308-313
Open Access | Times Cited: 2
Current and Emerging Sleep Interventions for Older Adults with or without Mild Cognitive Impairment
Anastasia Suraev, Shawn Dexiao Kong, Zoe Menczel Schrire, et al.
Current Treatment Options in Neurology (2024) Vol. 26, Iss. 11, pp. 463-483
Open Access | Times Cited: 2
Validating lane drifts as a predictive measure of drug or sleepiness induced driving impairment
Frederick Vinckenbosch, Annemiek Vermeeren, Joris C. Verster, et al.
Psychopharmacology (2020) Vol. 237, Iss. 3, pp. 877-886
Open Access | Times Cited: 20
Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder
Bojan Lalovic, Oneeb Majid, Jagadeesh Aluri, et al.
The Journal of Clinical Pharmacology (2020) Vol. 60, Iss. 12, pp. 1642-1654
Open Access | Times Cited: 18
Disposition and Metabolism of [14C]Lemborexant in Healthy Human Subjects and Characterization of Its Circulating Metabolites
Takashi Ueno, T. Ishida, Jagadeesh Aluri, et al.
Drug Metabolism and Disposition (2020) Vol. 49, Iss. 1, pp. 31-38
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top